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and exacerbation in COPD, respectively. ZNF323/MPV17L hypermethyla-
tion may be involved in rapid lung function decline.
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Background and Aims: Spanish chronic obstructive pulmonary dis-
ease (COPD) guideline classifies COPD into 4 clinical phenotypes: non-
exacerbator (A), asthma-COPD overlap (B), exacerbator with emphysema
(C) and exacerbator with bronchitis (D).
Methods: A cross-sectional observational study of quality of life
(QOL) of COPD patients utilizing COPD Assessment Test (CAT), con-
ducted in University of Malaya Medical Center from 1 June 2017 –
31 May 2018.
Results: Of 220 patients traeted for COPD, 189 patients with post
bronchodilator Force Expiratory Volume in 1 second (FEV1)/Force Vital
Capacity (FVC) of <0.70 were recruited. Patients’ demographic, clinical
characteristics and CAT score are as shown in Table 1. Patients with
COPD phenotype C and D had poorer modified medical research center
(MMRC) functional status and global initiative of COPD (GOLD) class
based on their FEV1.
Patients with phenotype D had significantly higher total CAT score
than patients with other clinical phenotypes. Other than sleep quality,
patients with phenotype D had significantly higher score in every other
components, notably cough severity, phlegm volume, chest tightness,
breathlessness upon walking uphill, activity limitation at home, ability to
leave home and energy. There was no different in terms of total and com-
ponents CAT score of patients with phenotype A, B and C.
Conclusion: Patients with phenotype D had significant higher CAT
score, thus poorer quality of life and higher tendency of execebration.
This group of patients need better medical treatment and closer
monitoring.
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Background and Aims: The blood eosinophil count in patients with
COPD exacerbation is reported to be associated with response to ther-
apy, and it is also reported that patients with a severe eosinophilic COPD
exacerbation have a shorter length of hospitalization. However, there is
no report about the change in blood eosinophil count during the course of
COPD exacerbation and its significance. So we examined the utility of
blood eosinophil count before and after COPD exacerbation in predicting
future exacerbation risk.
Methods: We retrospectively investigated consecutive hospitalized
patients due to COPD exacerbation at Iizuka Hospital between December
2012 and December 2017. Inclusion criteria were as follows: Patients
who underwent the following blood eosinophil count tests: at stable state
before and after the admission, and chest computed tomography
(on admission); Patients who have continued visiting our institution after
the discharge. Thr following data were extracted from medical records:
age, sex, BMI, pulmonary function tests (FEV1%predicted), severity of
emphysema (Goddard classification), blood eosinophil count [at stable
states before and after the admission (Eo-b and Eo-a, respectively)], fre-
quency of COPD exacerbation, length of stay, and clinical course during
and after admission.
Results: 130 patients were included. During the follow-up period
(mean, 2.6 years), 77 patients did not experience COPD exacerbation
(non-Ex group) and 53 patients experienced it more than once
(Ex group). There was a statistically significant difference between the
two groups in Eo-a (median, 242.1/μl in non-Ex vs 150.0/μl in Ex group;
P = 0.002), not in Eo-b (205.0/μl vs 176.6/μl, P = 0.634).
Conclusion: Low blood eosinophil count at a stable state after
COPD exacerbation may be one of the risk factors of future COPD
exacerbation.
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Background and Aims: Chronic Obstructive Pulmonary Disease
(COPD) is a respiratory disorder of significant public health importance. It
is presently ranked as the third most important cause of death worldwide.
A diagnosis of COPD is established by a post bronchodilator (BD) forced
expiratory volume in the first second (FEV1)/forced vital capacity (FVC)
ratio of less than 0.7 or the lower limit of normal (LLN). It is largely under
diagnosed in developing countries for various reasons including lack of
affordable spirometers in primary care settings. The peak expiratory flow
rate (PEFR) test measures how fast a person can exhale. A portable
Editorial material and organization © 2018 Asian Pacific Society of Respirology.
Copyright of individual abstracts remains with the authors
Respirology (2018) 23 (Suppl. 2), 90–334
246 Abstracts
